Compare Wahed FTSE USA Shariah ETF (HLAL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Natera Inc. Common Stock — how do they compare? Wahed FTSE USA Shariah ETF trades at $75 (market cap $996.16M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 57.2× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is more actively traded (36,084 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 67 Days and Natera Inc. Common Stock for 0 Days on average.
| HLAL | NTRA | |
|---|---|---|
Market Cap | $996.16M | $57.03B |
Volume | 36,084 | 1,131,157 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $425.64 |
52-Week Low | $57.46 | $179.42 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.90, showing modest daily gains of 0.13% with a bullish technical outlook supported by moving averages. The stock faces resistance near $77-78 while finding support at $75-74 levels. Key technical indicators show mixed signals with RSI suggesting potential overbought conditions on shorter timeframes.
Investment outlook remains data-dependent given limited fundamental information availability. The technical setup suggests near-term upside potential if resistance levels are breached, though momentum indicators warrant caution. Investors should await upcoming financial disclosures for clearer fundamental assessment.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
